Art. -Nr.: HY-N2302

Fucoxanthin

(Synonyms: all-trans-Fucoxanthin)

14 Cited Publications

Kundenbewertung

Based on 14 publication(s) in Google Scholar

Fucoxanthin (all-trans-Fucoxanthin) is a marine carotenoid and shows anti-obesity, anti-diabetic, anti-oxidant, anti-inflammatory and anticancer activities.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.54%
CAS. Nr.: 3351-86-8
Formel: C₄₂H₅₈O₆
Molecular Weight:658.91

Speicherung:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

Fucoxanthin Chemical Structure

CAS. Nr.: 3351-86-8

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (14)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Fucoxanthin (all-trans-Fucoxanthin) is a marine carotenoid and shows anti-obesity, anti-diabetic, anti-oxidant, anti-inflammatory and anticancer activities^[1]^[2]^[3]^[4]^[5]^[6]^[7]^[8]^[9].

IC₅₀ & Target

PPARγ

UCP1

PPARα

iNOS

Caspase 3

Caspase-8

Caspase 9

SOD

ERK2

Alle PPAR Isoform-spezifische Produkte anzeigen :

Alle NO Synthase Isoform-spezifische Produkte anzeigen :

Alle Caspase Isoform-spezifische Produkte anzeigen :

Alle ERK Isoform-spezifische Produkte anzeigen :

In Vitro

Fucoxanthin (2.8-6.2 µM, 24 h) shows obvious bacteriostatic effect on all tested Mtb strains, with MIC values of 2.8-4.1 µM^[4].
Fucoxanthin (0-25 µM, 24 h) inhibits the proliferation of HeLa and SiHa cervical cancer cell lines and promotes cell stasis in the G0/G1 cell cycle phase^[5].
Fucoxanthin (10 µM, 12 h) inhibits the cell viability of HTLV-1-infected T cell lines by inducing G1 cell cycle arrest and apoptosis, thereby exhibiting anticancer activity^[7].
Fucoxanthin (0-100 µg/mL, 24 h) dose-dependent inhibits the expression of TNF-α, PGE2, iNOS and COX-2 proteins in RAW 264.7 cells^[8].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[8]

Cell Line:

RAW 264.7 cells
Concentration:

0-100 µg/mL,
Incubation Time:

24 h
Result:

Inhibited LPS-induced iNOS and COX-2 protein expression in RAW 264.7 cells.
Decreased NO and PEG2 concentrations in LPS-induced RAW 264.7 cells.

RT-PCR^[6]

Cell Line:

Hela and SiHa cells
Concentration:

10 µg/mL
Incubation Time:

4 h
Result:

Down-regulated N-myc mRNA expression.

In Vivo

Fucoxanthin (10-2000 mg/kg, p.o.) does not cause death or abnormal appearance in ICR mice and rats^[3].
Fucoxanthin (10-50 mg/kg/day, p.o.) can protect the cadmium-induced renal injury mouse model by improving the antioxidant capacity of mice^[9].
Fucoxanthin (0.1-10 mg/kg, i.v.) shows a dose-dependent anti-ocular inflammatory effect on EIU (endotoxin-induced uveitis) ^[8].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

6-week-old male and female Crl:CD (SD) rats, 6-week-old male and female ICR mice^[3]
Dosage:

10-2000 mg/kg/day for 28/30 days
Administration:

p.o.
Result:

No abnormal appearance or death occurred in the rats and ICR mice.
Significantly increased the concentration of serum total cholesterol in rats and ICR mice.

Animal Model:

mice models subjected to cadmium-induced kidney damage, Six- to eight-week-old male Kunming mice (weight, 22–26 gram (g)/per mouse)^[9]
Dosage:

10-50 mg/kg/day for 14 days
Administration:

p.o.
Result:

Blocked the Cd-induced increase in the cadmium level.
Significantly decreased the levels of blood urea nitrogen, creatinine and lipid peroxidation, and increased the levels of SOD, POD and reduced glutathione.
Helped to restore mitochondrial structure and inhibit renal cell apoptosis.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 3351-86-8
Appearance Solid
Molecular Weight 658.91
Formel C₄₂H₅₈O₆
Color Purple to purplish red
SMILES

O=C(/C(C)=C/C=C/C(C)=C/C=C/C=C(C)/C=C/C=C(C)/C([H])=[C@@]=C([C@@]1(O)C)C(C)(C[C@H](OC(C)=O)C1)C)C[C@]2(C3(C)C)[C@@](C)(C[C@@H](O)C3)O2
Synonyms

all-trans-Fucoxanthin
Structure Classification
- Others
Initial Source
- Plants
- other families
- Marine natural products
- Marine algae
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (14)

All Cell Proliferation/Viability AssayCell Migration/Invasion AssayWB2D/3D Cell Culture and DifferentiationIF

Sort by:

Journal Impact Factor

Phytomedicine

Fucoxanthin inhibits gastric cancer lymphangiogenesis and metastasis by regulating Ran expression. [Abstract]

2023 Sep:118:154926. PMID: 37392675

Fucoxanthin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2023 Sep:118:154926. [Abstract]

Fucoxanthin (6.25-100 μM) repressed the proliferation of GC cells at 24 h or 48 h in HGC-27 cells.

Fucoxanthin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2023 Sep:118:154926. [Abstract]

Microscopy images of cellular migration and invasion (scale bar = 100 μm). The morphology and number of migrating cells were evaluated via a Transwell assay following 24 h of treatment with different concentrations of Fucoxanthin (25, 50, and 100 μM). The invasive capacity of HLECs was determined by counting the cells that migrated across the membrane.

Fucoxanthin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2023 Sep:118:154926. [Abstract]

Fucoxanthin (25-100 μM; 24 h) inhibited tube formation in HLECs by regulating the secretion of VEGF-C in HGC-27 cells.

Fucoxanthin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2023 Sep:118:154926. [Abstract]

Immunofluorescent images (VEGFR-3, green and LYVE-1, red) of tumor lymphatic vessels in nude mice. Immunofluorescent results showed that Fucoxanthin (100-500 μM; 50 µL; i.t.; 2 weeks) significantly decreased tumor lymphangiogenesis along with the expression of LYVE-1 and VEGF-C receptor VEGFR-3.
Food Funct

Fucoxanthin alleviated myocardial ischemia and reperfusion injury through inhibition of ferroptosis via the NRF2 signaling pathway. [Abstract]

2023 Nov 13;14(22):10052-10068. PMID: 37861458
RSC Pharm

2026 Mar 19.
Mol Med Rep

Fucoxanthin alleviates chondrocyte inflammation and osteoarthritis by modulating the JAK2/STAT3 signaling pathway. [Abstract]

2026 Aug;34(2):223. PMID: 42272246
Algal Res

2022: 102891.
Neural Plast

Fucoxanthin Inhibits the NMDA and AMPA Receptors Through Regulating the Calcium Response on Substantia Gelatinosa Neurons of the Trigeminal Subnucleus Caudalis in Juvenile Mice. [Abstract]

2025 Jan 31:2025:2553040. PMID: 39949835
Mol Biol Rep

Fucoxanthin regulates macrophage pyroptosis through the PI3K/AKT/mTOR signalling pathway. [Abstract]

2026 Jan 3;53(1):250. PMID: 41483374
Chem Biodivers

Bioassay-guided Isolation of SARS-CoV-2 Viral Entry Inhibitors From the Brown Algae Lobophora variegata Identifies Fucoxanthin as a Selective ACE-2/Spike Inhibitor. [Abstract]

2025 Aug 29:e01403. PMID: 40882140
PLoS One

Fucoxanthin ameliorates Propionibacterium acnes-induced ear inflammation in mice by modulating the IκBα/NF-κB signaling pathway and inhibiting NF-κB nuclear translocation. [Abstract]

2025 May 7;20(5):e0322950. PMID: 40333903
PLoS One

Fucoxanthin inhibits cardiac fibroblast transdifferentiation by alleviating oxidative stress through downregulation of BRD4. [Abstract]

2023 Sep 12;18(9):e0291469. PMID: 37699016
Discov Oncol

Fucoxanthin induces apoptosis and reverses epithelial-mesenchymal transition via inhibiting Wnt/β-catenin pathway in lung adenocarcinoma. [Abstract]

2022 Oct 3;13(1):98. PMID: 36192568
University of Puerto Rico

2026.
Research Square Print

November 9th, 2022
Biomed Pharmacother

Fucoxanthin rescues dexamethasone induced C2C12 myotubes atrophy. [Abstract]

2021 Jul:139:111590. PMID: 33865017

Fucoxanthin purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2021 Jul:139:111590. [Abstract]

Cell viability of C2C12 cells in different concentrations of Fucoxanthin (FX,1-100 μM; 24 h) and dexamethasone (10 μM).

Fucoxanthin purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2021 Jul:139:111590. [Abstract]

The results showed that treatment with 10 μM dexamethasone (DEX) led to a significant reduction in MyHC expression levels, whereas treatment with 10 μM Fucoxanthin (24 h) significantly attenuated this downregulation of MyHC expression.

Fucoxanthin purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2021 Jul:139:111590. [Abstract]

Morphological observation (magnification 200×; scale bar = 50 µm), MyHC staining (magnification 100×; scale bar = 50 µm) and quantification of myotubes. Ctrl = control group, DEX = dexamethasone (10 μM) treatment group, DEX + FX = dexamethasone (10 μM) combined with Fucoxanthin (10 μM; 24 h) treatment group, DEX + FX + EX527 = dexamethasone(10 μM) combined with Fucoxanthin(10 μM; 24 h) and EX-527 (SIRT1 inhibitor, 20 μM) treatment group.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 12.5 mg/mL (18.97 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.5177 mL

7.5883 mL

15.1766 mL

5 mM

0.3035 mL

1.5177 mL

3.0353 mL

10 mM

0.1518 mL

0.7588 mL

1.5177 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 1.25 mg/mL (1.90 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 1.25 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 1.25 mg/mL (1.90 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 1.25 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (277 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Gammone MA, et al. Anti-obesity activity of the marine carotenoid fucoxanthin. Mar Drugs. 2015 Apr 13;13(4):2196-214. [Content Brief]

[2]. Méresse S, Fodil M, Fleury F, Chénais B. Fucoxanthin, a Marine-Derived Carotenoid from Brown Seaweeds and Microalgae: A Promising Bioactive Compound for Cancer Therapy. Int J Mol Sci. 2020;21(23):9273. [Content Brief]

[3]. Yoshimi Niwano, et al. In Vivo and in Vitro Toxicity Studies of Fucoxanthin, a Marine Carotenoid. null. 2011;0 (0):319-328.

[4]. Šudomová M, et al. A Microbiological, Toxicological, and Biochemical Study of the Effects of Fucoxanthin, a Marine Carotenoid, on Mycobacterium tuberculosis and the Enzymes Implicated in Its Cell Wall: A Link Between Mycobacterial Infection and Autoimmune Diseases. Mar Drugs. 2019 Nov 14;17(11):641. [Content Brief]

[5]. Ye G, et al. Fucoxanthin may inhibit cervical cancer cell proliferation via downregulation of HIST1H3D. J Int Med Res. 2020 Oct;48(10):300060520964011. [Content Brief]

[6]. Okuzumi J, et al. Inhibitory effects of fucoxanthin, a natural carotenoid, on N-myc expression and cell cycle progression in human malignant tumor cells. Cancer Lett. 1990 Nov 19;55(1):75-81. [Content Brief]

[7]. Ishikawa C, et al. Anti-adult T-cell leukemia effects of brown algae fucoxanthin and its deacetylated product, fucoxanthinol. Int J Cancer. 2008 Dec 1;123(11):2702-12. [Content Brief]

[8]. Shiratori K, et al. Effects of fucoxanthin on lipopolysaccharide-induced inflammation in vitro and in vivo. Exp Eye Res. 2005 Oct;81(4):422-8. [Content Brief]

[9]. Yang H, et al. Role of Fucoxanthin towards Cadmium-induced renal impairment with the antioxidant and anti-lipid peroxide activities. Bioengineered. 2021 Dec;12(1):7235-7247. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.5177 mL	7.5883 mL	15.1766 mL	37.9415 mL
	5 mM	0.3035 mL	1.5177 mL	3.0353 mL	7.5883 mL
	10 mM	0.1518 mL	0.7588 mL	1.5177 mL	3.7941 mL
	15 mM	0.1012 mL	0.5059 mL	1.0118 mL	2.5294 mL

Fucoxanthin

14 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Fucoxanthin

Anti-Infection Compound Library

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Immunology/Inflammation Compound Library

MAPK Compound Library

Metabolism/Protease Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Clinical Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Covalent Screening Library

Anti-diabetic Compound Library

Lipid Compound Library

Oxygen Sensing Compound Library

Anti-Cardiovascular Disease Compound Library

Antibacterial Compound Library

Medicine Food Homology Compound Library

Pyroptosis Compound Library

Orally Active Compound Library

Glutamine Metabolism Compound Library

Traditional Chinese Medicine Active Compound Library

Neuroprotective Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Lipid Metabolism Compound Library

Anti-Cancer Natural Product Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Anti-Pulmonary Fibrosis Compound Library

Nuclear Receptor Compound Library

Anti-Aging Natural Product Library

Pain-Related Compound Library

Marine-Sourced Natural Product Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

Anti-Aging Compound Library Mini

MCE Bioactive Compound Library

Covalent Screening Library Plus

Natural Product Library Plus

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Dietary Supplement Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

Lactic Acid Metabolic Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Metabolite Library

Cosmetic Ingredient Compound Library

Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library

Natural Product Diversity Scaffold Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Fucoxanthin

Alle PPAR Isoform-spezifische Produkte anzeigen

Alle NO Synthase Isoform-spezifische Produkte anzeigen

Alle Caspase Isoform-spezifische Produkte anzeigen

Alle ERK Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (14)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Fucoxanthin Related Classifications